EnzymeBioSystems announced that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the company. Management has been working on developing proprietary OTC product(s) to be sold under the EnzymeBioSystems label.